Editas Medicine, Inc.
EDIT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EDIT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EDIT
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based gene-editing therapies, with its lead candidate EDIT-401 targeting liver diseases and a cash runway extending into Q3 2027.
Key risk: Clinical development uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Editas Medicine, Inc..
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based gene-editing therapies, with its lead candidate EDIT-401 targeting liver diseases and a cash runway extending into Q3 2027.
- Lead candidate EDIT-401 is an in vivo gene-editing therapy for liver diseases, with plans to initiate a first-in-human study in 2026 and achieve early in vivo human proof-of-concept data by end of 2026 [sec · filed 2026-05-26].
- Cash and equivalents were $184.5M as of 2026-06-30, with a cash runway extended into the third quarter of 2027 through financial discipline and an at-the-market offering facility [sec · filed 2026-04-28].
- Total revenue was $11.9M, net loss was -$18.2M, shareholders' equity was $19.2M, and total debt was $55.7M as of 2026-06-30 [sec].
- The company is advancing its LNP platform for extrahepatic delivery, targeting multiple tissues through different targeting ligands [sec · filed 2026-04-28].
- Editas has an accumulated deficit of $1.6 billion as of December 31, 2025, and expects to continue incurring significant expenses and operating losses [sec_mda · as of 2026-03-09].
What works
- Editas has extended its cash runway into Q3 2027, providing a financial buffer to advance EDIT-401 toward key milestones [sec · filed 2026-04-28].
- The company's LNP platform enables extrahepatic delivery, potentially broadening the therapeutic applications of its gene-editing technology [sec · filed 2026-04-28].
- EDIT-401 is progressing toward clinical trials, with a first-in-human study planned for 2026 and proof-of-concept data expected by end of 2026 [sec · filed 2026-05-26].
What to weigh
- Editas has an accumulated deficit of $1.6 billion as of December 31, 2025, and expects to continue incurring significant expenses and operating losses [sec_mda · as of 2026-03-09].
- The company has no approved products and does not expect to generate significant recurring revenue unless regulatory approval and commercialization are achieved [sec_mda · as of 2026-08-05].
- Future funding requirements depend on many uncertain factors, including the costs of developing EDIT-401 and other candidates, and the company may need additional capital sooner than expected [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Editas plans to initiate a first-in-human study for EDIT-401 in 2026 and achieve early in vivo human proof-of-concept data by end of 2026.
“initiating a first-in-human study for EDIT-401 in 2026 and achievement of early in vivo human proof-of-concept data for EDIT-401 by the end of 2026”
SEC filings · May 26, 2026
Editas extended its cash runway into Q3 2027 through financial discipline and an at-the-market offering facility.
“we extended our cash runway into the third quarter of 2027, placing us in a strong position to build on our achievements in 2025 and drive EDIT-401 toward upcoming milestones”
SEC filings · April 28, 2026
Editas has an accumulated deficit of $1.6 billion as of December 31, 2025.
“As of December 31, 2025, we had an accumulated deficit of $1.6 billion.”
SEC MD&A · March 9, 2026
Editas' LNP platform enables extrahepatic delivery through substitution of targeting ligands.
“our LNP platform enables us to target multiple tissues through the substitution of different targeting ligands conjugated to the LNP”
SEC filings · April 28, 2026
Risks & what to watch (4)›
Key risks
- Clinical development uncertainty — EDIT-401 is preclinical; clinical trials may fail or be delayed, requiring significant time and resources [sec_mda · as of 2026-08-05].
- Capital needs and dilution — Editas may need additional funding sooner than expected, potentially diluting shareholders [sec_mda · as of 2026-08-05].
- No approved products or revenue — Editas has no marketed products and expects no significant recurring revenue until regulatory approval [sec_mda · as of 2026-08-05].
- Intellectual property costs — Editas must reimburse licensors for patent prosecution and maintenance, adding to expenses [sec_mda · as of 2026-08-05].
What to watch
- Initiation of the first-in-human study for EDIT-401 in 2026 [sec · filed 2026-05-26].
- Achievement of early in vivo human proof-of-concept data for EDIT-401 by end of 2026 [sec · filed 2026-05-26].
- Submission of a Clinical Trial Notification (CTN) in Australia for EDIT-401 by mid-2026 [sec · filed 2026-05-26].
- Cash runway status and any additional financing activities as the company approaches Q3 2027 [sec · filed 2026-04-28].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Editas Medicine, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Editas Medicine, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.7 months
D/E 1.25 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
205
Total value held
$122.0M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,263,312 | $22.9M |
| vanguard capital management llc | 8,408,738 | $20.8M |
| renaissance technologies llc | 3,972,160 | $9.8M |
| vanguard portfolio management llc | 3,148,570 | $7.8M |
| geode capital management, llc | 2,311,789 | $5.7M |
| state street corp | 2,076,122 | $5.1M |
| d. e. shaw & co., inc. | 1,943,893 | $4.8M |
| two sigma investments, lp | 1,549,063 | $3.8M |
| aqr capital management llc | 1,370,497 | $3.4M |
| raymond james financial inc | 1,293,848 | $3.2M |
Showing top 10 of 205 institutional holders of Editas Medicine, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 12.2%
- Days to cover
- 6.6
- Shares short
- 11,941,373
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EDIT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Editas Medicine, Inc.?
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based gene-editing therapies, with its lead candidate EDIT-401 targeting liver diseases and a cash runway extending into Q3 2027.
What is Editas Medicine, Inc.'s lead drug candidate?
Editas Medicine, Inc.'s most advanced tracked candidate is CASGEVY (exagamglogene autotemcel) (Approved) for Sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Who is the CEO of Editas Medicine, Inc.?
Dr. Gilmore O'Neill M.D. is the chief executive officer of Editas Medicine, Inc. (EDIT).
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. (EDIT) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Editas Medicine, Inc. focus on?
Editas Medicine, Inc. develops therapies across Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.